IQVIA Holdings
Market Cap
US$27.9b
Last Updated
2019/12/12 00:15 UTC
Data Sources
Company Financials +
Executive Summary
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with questionable track record.
Similar Companies
Share Price & News
How has IQVIA Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IQV has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-1.0%
IQV
0.8%
US Life Sciences
0.8%
US Market
1 Year Return
18.4%
IQV
20.1%
US Life Sciences
17.8%
US Market
Return vs Industry: IQV underperformed the US Life Sciences industry which returned 20.1% over the past year.
Return vs Market: IQV matched the US Market which returned 17.8% over the past year.
Shareholder returns
| IQV | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.0% | 0.8% | 0.8% |
| 30 Day | 0.6% | 8.3% | 1.8% |
| 90 Day | -5.0% | 6.7% | 4.1% |
| 1 Year | 18.4%18.4% | 20.3%20.1% | 20.4%17.8% |
| 3 Year | 78.6%78.6% | 103.5%101.9% | 45.9%36.4% |
| 5 Year | 142.2%142.2% | 133.2%130.0% | 68.1%49.6% |
Price Volatility Vs. Market
How volatile is IQVIA Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Does IQVIA Holdings (NYSE:IQV) Have A Healthy Balance Sheet?3 weeks ago | Simply Wall St
Should You Be Worried About Insider Transactions At IQVIA Holdings Inc. (NYSE:IQV)?1 month ago | Simply Wall St
IQVIA Holdings Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting NowValuation
Is IQVIA Holdings undervalued compared to its fair value and its price relative to the market?
115.97x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: IQV ($143.84) is trading above our estimate of fair value ($96.96)
Significantly Below Fair Value: IQV is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: IQV is poor value based on its PE Ratio (116x) compared to the Life Sciences industry average (35.5x).
PE vs Market: IQV is poor value based on its PE Ratio (116x) compared to the US market (18.4x).
Price to Earnings Growth Ratio
PEG Ratio: IQV is poor value based on its PEG Ratio (3.8x)
Price to Book Ratio
PB vs Industry: IQV is good value based on its PB Ratio (4.6x) compared to the US Life Sciences industry average (5.2x).
Next Steps
Future Growth
How is IQVIA Holdings forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
30.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IQV's forecast earnings growth (30.5% per year) is above the savings rate (1.7%).
Earnings vs Market: IQV's earnings (30.5% per year) are forecast to grow faster than the US market (14.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: IQV's revenue (7.6% per year) is forecast to grow faster than the US market (7.4% per year).
High Growth Revenue: IQV's revenue (7.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IQV's Return on Equity is forecast to be high in 3 years time (22.3%)
Next Steps
Past Performance
How has IQVIA Holdings performed over the past 5 years?
12.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IQV has high quality earnings.
Growing Profit Margin: IQV's current net profit margins (2.2%) are lower than last year (11.9%).
Past Earnings Growth Analysis
Earnings Trend: IQV's earnings have grown by 12.6% per year over the past 5 years.
Accelerating Growth: IQV's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: IQV had negative earnings growth (-80%) over the past year, making it difficult to compare to the Life Sciences industry average (34.6%).
Return on Equity
High ROE: IQV's Return on Equity (4.4%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is IQVIA Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: IQV's short term assets ($4.0B) exceed its short term liabilities ($3.6B).
Long Term Liabilities: IQV's short term assets ($4.0B) do not cover its long term liabilities ($12.9B).
Debt to Equity History and Analysis
Debt Level: IQV's debt to equity ratio (181.1%) is considered high.
Reducing Debt: IQV had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: IQV's debt is not well covered by operating cash flow (10.8%).
Interest Coverage: IQV's interest payments on its debt are not well covered by EBIT (2x coverage).
Balance Sheet
Inventory Level: IQV has a low level of unsold assets or inventory.
Debt Coverage by Assets: IQV's debt is not covered by short term assets (assets are 0.3x debt).
Next Steps
Dividend
What is IQVIA Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate IQV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate IQV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IQV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IQV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: IQV is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IQV's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of IQVIA Holdings's salary, the management and board of directors tenure and is there insider trading?
3.2yrs
Average management tenure
CEO
Ari Bousbib (58yo)
3.2yrs
Tenure
US$16,461,779
Compensation
Mr. Ari Bousbib serves as Chairman and Chief Executive Officer at IQVIA Holdings Inc. since October 2016 and also serves as its President. He has been the Chairman, Chief Executive Officer and President of ...
CEO Compensation Analysis
Compensation vs Market: Ari's total compensation ($USD16.46M) is above average for companies of similar size in the US market ($USD10.94M).
Compensation vs Earnings: Ari's compensation has been consistent with company performance over the past year.
Management Age and Tenure
3.2yrs
Average Tenure
55yo
Average Age
Experienced Management: IQV's management team is considered experienced (3.2 years average tenure).
Board Age and Tenure
3.2yrs
Average Tenure
60yo
Average Age
Experienced Board: IQV's board of directors are considered experienced (3.2 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Company |
| Shares | 1,810,887 |
| Max Price | US$156.85 |
| Entity | Company |
| Shares | 2,616,028 |
| Max Price | US$156.85 |
| Entity | Company |
| Shares | 573,085 |
| Max Price | US$156.85 |
| Entity | Individual |
| Role | Senior Key Executive President of Information & Technology Solutions |
| Shares | 4,278 |
| Max Price | US$158.50 |
| Entity | Individual |
| Role | Senior Key Executive President of Information & Technology Solutions |
| Shares | 6,945 |
| Max Price | US$158.53 |
| Entity | Company |
| Shares | 868,684 |
| Max Price | US$140.80 |
| Entity | Company |
| Shares | 4,044,480 |
| Max Price | US$140.80 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Ari Bousbib (58yo)
Chairman
- Tenure: 3.2yrs
- Compensation: US$16.46m
Mike McDonnell (55yo)
Executive VP & CFO
- Tenure: 4yrs
- Compensation: US$2.57m
W. Staub (56yo)
President of Research & Development Solutions
- Tenure: 3.1yrs
- Compensation: US$2.24m
Kevin Knightly (58yo)
President of Information & Technology Solutions
- Tenure: 3.2yrs
- Compensation: US$2.19m
Eric Sherbet (55yo)
Executive VP
- Tenure: 1.8yrs
- Compensation: US$1.48m
Manny Korakis (45yo)
Senior VP
- Tenure: 1.1yrs
Alejandro Martinez
Chief Information Officer
- Tenure: 5yrs
Jeff Spaeder
Senior VP
- Tenure: 0yrs
Andrew Markwick
Vice President of Investor Relations
- Tenure: 0yrs
Marla Kessler (49yo)
Senior Vice President of Strategy
- Tenure: 0yrs
Board Members
John Danhakl (63yo)
Independent Director
- Tenure: 3.2yrs
John Connaughton (56yo)
Independent Director
- Tenure: 11.9yrs
Ari Bousbib (58yo)
Chairman
- Tenure: 3.2yrs
- Compensation: US$16.46m
John Leonard (62yo)
Lead Director
- Tenure: 1.4yrs
- Compensation: US$325.57k
Mike Evanisko (69yo)
Independent Director
- Tenure: 9.6yrs
- Compensation: US$309.95k
Jonathan Coslet (55yo)
Independent Director
- Tenure: 16.9yrs
Ron Rittenmeyer (72yo)
Independent Director
- Tenure: 3.2yrs
- Compensation: US$334.95k
Colleen Goggins (65yo)
Independent Director
- Tenure: 2.4yrs
- Compensation: US$312.45k
Todd Sisitsky (48yo)
Independent Director
- Tenure: 3.2yrs
James Fasano (49yo)
Independent Director
- Tenure: 3.2yrs
Company Information
IQVIA Holdings Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: IQVIA Holdings Inc.
- Ticker: IQV
- Exchange: NYSE
- Founded: 1982
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$27.910b
- Shares outstanding: 194.04m
- Website: https://www.iqvia.com
Number of Employees
Location
- IQVIA Holdings Inc.
- 4820 Emperor Boulevard
- Durham
- North Carolina
- 27703
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| IQV | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | May 2013 |
| QTS | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | May 2013 |
| 0JDM | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | May 2013 |
| IQV * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | May 2013 |
| IQVH | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | May 2013 |
Biography
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates throug ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/12 00:15 |
| End of Day Share Price | 2019/12/11 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.